Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

CEO

Ron Cohen

Pekerja

111

Negara

Amerika Syarikat

ISIN

US00484M1062

Penyenaraian

STU

CDG.STU

0 Comments

Kongsi pendapat anda

FAQ

Berapakah harga saham Acorda Therapeutics hari ini?▼

Harga semasa CDG.STU ialah €9.36 EUR — telah meningkat sebanyak +0% dalam 24 jam yang lalu. Pantau prestasi harga saham Acorda Therapeutics dengan lebih dekat pada carta.

Apakah simbol saham Acorda Therapeutics?▼

Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham Acorda Therapeutics didagangkan di bawah simbol CDG.STU.

Berapa ramai pekerja yang dimiliki oleh Acorda Therapeutics?▼

Sehingga Julai 10, 2026, syarikat mempunyai 111 pekerja.

Acorda Therapeutics terletak dalam sektor apa?▼

Acorda Therapeutics beroperasi dalam sektor Pembuatan.

Bilakah Acorda Therapeutics menyiapkan split saham?▼

Acorda Therapeutics tidak mempunyai sebarang split baru-baru ini.

Di manakah ibu pejabat Acorda Therapeutics?▼

Ibu pejabat Acorda Therapeutics terletak di Ardsley, Amerika Syarikat.